Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
NHEJ1 encodes non-homologous end joining factor 1 (299 aa). DNA repair protein involved in DNA non-homologous end joining (NHEJ); it is required for double-strand break (DSB) repair and V(D)J recombination and is also involved in telomere maintenance. Highest expression in Testis (23.6 TPM) and Cervix Ectocervix (18.7 TPM).
Microphthalmia/coloboma 13 is associated with mutations in the NHEJ1 gene on chromosome 2.
The NHEJ1 protein participates in p-T2609,S2612,T2638,T2647-PRKDC:XRCC5:XRCC6:p-S516,S645-DCLRE1C:XRCC4:LIG4:NHEJ1:POLL,POLM:Ligatable DNA DSB ends, p-T2609,S2612,T2638,T2647-PRKDC:XRCC5:XRCC6:p-S516,S645-DCLRE1C:XRCC4:LIG4:NHEJ1:POLL,POLM:Extended ligatable DNA DSB ends, and XRCC4:LIG4, NHEJ1 and POLL or POLM bind DNA DSBs in NHEJ pathways.
NHEJ1 is classified as a druggable target with score 0.0.
Genetic testing for NHEJ1 is available. Testing is considered confirmatory for diagnosis.
No clinical trials have been registered for microphthalmia/coloboma 13.
1 publication has been identified in PubMed for microphthalmia/coloboma 13. Research spans Basic Science / Preclinical (100%).
Ceroni F (2024). [PMID: 39455595](https://pubmed.ncbi.nlm.nih.gov/39455595/). *Nat Commun*. [Basic Science / Preclinical]
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
Online Mendelian Inheritance in Man